Related Experiment Video
Updated: Jul 8, 2026
Contrast Enhanced Ultrasound Imaging for Assessment of Spinal Cord Blood Flow in Experimental Spinal Cord Injury
Published on: May 7, 2015
Serum S100-Beta as a Biomarker for Neurological Recovery in Acute Spinal Cord Injury (ASCI): A Prospective
Shah Waliullah1, Nagendra Kumar1, Binod Kumar1
1Department of Orthopedic Surgery, King George's Medical University, Lucknow, IND.
Background:
Acute spinal cord injury (ASCI) leads to severe neurological deficits with limited prognostic biomarkers. However, S100-beta (S100B), a calcium-binding protein, emerges as a beacon of hope, showing potential as a serological marker of ASCI severity and recovery, inspiring further research and exploration in this field.
Methods:
This prospective case-control study included 26 patients with ASCI and 26 age- and sex-matched healthy controls. Serum S100B levels were measured using enzyme-linked immunosorbent assay (ELISA) at baseline, two, and six weeks. Neurological recovery was evaluated using the American Spinal Injury Association (ASIA) Impairment Scale.
Results:
Serum S100B levels in ASCI patients were significantly higher than controls at baseline (0.95 ± 0.16 µg/L vs. 0.028 ± 0.02 µg/L; p < 0.05) and at two weeks (p < 0.05). Levels normalized after six weeks (p > 0.05). Also, when comparing serum S100B levels among cases, it was higher in paraplegia than in the paraparesis group. Elevated serum S100B levels correlated with greater injury severity and poorer neurological outcomes.
Conclusion:
S100B is a promising biomarker for early ASCI severity and recovery. However, further large-scale studies are required to establish its clinical utility.
More Related Videos
09:08A Neurosphere Assay to Evaluate Endogenous Neural Stem Cell Activation in a Mouse Model of Minimal Spinal Cord Injury
Published on: September 13, 2018
08:17Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis
Published on: February 23, 2024